Concizumab may be effective prophylaxis for hemophilia A or B with inhibitors

September 3 2023, by Lori Solomon



Patients with hemophilia A or B with inhibitors have a lower annualized

bleeding rate with concizumab than with no prophylaxis, according to a phase 3 study published online Aug. 31 in the *New England Journal of Medicine*.

Tadashi Matsushita, M.D., Ph.D., from Nagoya University Hospital in Japan, and colleagues evaluated the safety and efficacy of concizumab in patients with hemophilia A or B with inhibitors. As part of the explorer7 phase 3 trial, participants were randomly assigned to receive no prophylaxis for at least 24 weeks (group 1; 19 patients) or to receive concizumab prophylaxis for at least 32 weeks (group 2; 33 patients), or they were nonrandomly assigned to receive concizumab prophylaxis for at least 24 weeks (groups 3 and 4; 81 patients).

The researchers found that the estimated mean annualized bleeding rate in group 1 was 11.8 episodes versus 1.7 episodes in group 2 (rate ratio, 0.14; P

"Concizumab represents a novel, subcutaneous treatment option in patients with hemophilia A or B with inhibitors that can potentially improve long-term outcomes," the authors write.

More information: Tadashi Matsushita et al, Phase 3 Trial of Concizumab in Hemophilia with Inhibitors, *New England Journal of Medicine* (2023). DOI: 10.1056/NEJMoa2216455

H. Marijke van den Berg et al, Hemostasis—A Balancing Act, *New England Journal of Medicine* (2023). DOI: 10.1056/NEJMe2304535

https://medicalxpress.com/news/2023-09-concizumab-effective-prophylaxis-hemophilia-inhibitors.html